OSI-027
As of the edition of 20 October 2026, OSI-027 is a small molecule: stopped in 2022; acts on MTOR.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2022
- Kind
- Small molecule
- Registered trials
- 2, 1 stopped early
- Disease areas
- Blood and lymph; Cancer; Immune system; Inherited and neonatal
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| MTOR | Serine/threonine-protein kinase mTOR | P42345 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 1 | 0 | 1 |
| All trials | 2 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Astellas | Lead sponsor of trials | 2008 to now |
| Avalo Therapeutics | Lead sponsor of trials | 2021 to now |